The FDA will not grant approval to Eli Lilly’s retatrutide before the end of 2026, leaving the investigational once-weekly triple hormone receptor agonist in Phase 3 limbo. As of July 2026 retatrutide had not been approved and Lilly will still be preparing the application it plans to file later in…